CCR5, RANTES and CX3CR1 polymorphisms: Possible genetic links with acute heart rejection

Transplantation

Volumn 80, Issue 9, 2005, Pages 1309-1315

  Simeoni, Eleonora ^a   Vassalli, Giuseppe ^a   Seydoux, Charles ^a   Ramsay, David ^b   Noll, Georg ^b   Von Segesser, Ludwig K ^a   Fleury, Sylvain ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Acute rejection; Chemokine receptors; Chemokines; Genetic polymorphism; Genotyping; Heart transplantation

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR1; RANTES; CHEMOKINE RECEPTOR; CX3CR1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ACUTE GRAFT REJECTION; ARTICLE; CARDIAC GRAFT REJECTION; CORRELATION ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAPLOTYPE; HEART TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; ACUTE DISEASE; ALLELE; COHORT ANALYSIS; GENETICS; GRAFT REJECTION; IMMUNOLOGY; RETROSPECTIVE STUDY;

ACUTE DISEASE; ALLELES; COHORT STUDIES; GRAFT REJECTION; HAPLOTYPES; HEART TRANSPLANTATION; HUMANS; MEMBRANE PROTEINS; POLYMORPHISM, GENETIC; RANTES; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RETROSPECTIVE STUDIES;

EID: 28544432924     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000178378.53616.ca     Document Type: Article

References (44)

1. Melter M, McMahon G, Fang J, et al. Current understanding of chemokine involvement in allograft transplantation. Pediatr Transplant 1999; 3: 10.
2. Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12: 511.
3. Taub DD, Sayers TJ, Carter CR, Ortaldo JR. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol 1995; 155: 3877.
4. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669.
5. Rot A, Krieger M, Brunner T, et al. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med 1992; 176: 1489.
6. Vaddi K, Newton RC. Comparison of biological responses of human monocytes and THP-1 cells to chemokines of the intercrine-beta family. J Leukoc Biol 1994; 55: 756.
7. Uguccioni M, D'Apuzzo M, Loetscher M, et al. Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur J Immunol 1995; 25: 64.
8. Kuna P, Reddigari SR, Schall TJ, et al. RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils. J Immunol 1992; 149: 636.
9. Kapp A, Zeck-Kapp G, Czech W, Schopf E. The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF. J Invest Dermatol 1994; 102: 906.
10. Fairchild RL, VanBuskirk AM, Kondo T, et al. Expression of chemokine genes during rejection and long-term acceptance of cardiac allogratts. Transplantation 1997; 63:1807.
11. Azzawi M, Hasleton PS, Geraghty P J, et al. RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. J Heart Lung Transplant 1998; 17: 881.
12. Mulligan MS, McDuffie JE, Shanley TP, et al. Role of RANTES in experimental cardiac allograft rejection. Exp Mol Pathol 2000; 69: 167.
13. Robinson LA, Nataraj C, Thomas DW, et al. A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol 2000; 165: 6067.
14. Umehara H, Bloom ET, Okazaki T, et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34.
15. Horuk R, Clayberger C, Krensky AM, et al. A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 2001; 276: 4199.
16. Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72: 1199.
17. Gao W, Topham PS, King JA, et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000; 105: 35.
18. Haskell CA, Hancock WW, Salant DJ, et al. Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001; 108: 679.
19. Mummidi S, Bamshad M, Ahuja SS, et al. Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specitic transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus. J Biol Chem 2000; 275: 18946.
20. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5Delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004; 10: 434.
21. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357: 1758.
22. Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002; 13: 754.
23. Moatti D, Faure S, Fumeron F, et al. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 2001; 97: 1925.
24. McDermott DH, Halcox JP, Schenke WH, et al. Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res 2001; 89: 401.
25. Billingham ME, Cary NR, Hammond ME, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587.
26. Hoshinaga K, Mohanakumar T, Goldman MH, et al. Clinical significance of in situ detection of T lymphocyte subsets and monocyte/macrophage lineages in heart allografts. Transplantation 1984; 38: 634.
27. Gassel AM, Hansmann ML, Radzun HJ, Weyand M. Human cardiac allograft rejection. Correlation of grading with expression of different monocyte/macrophage markers. Am J Clin Pathol 1990; 94: 274.
28. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and receptor-gene expression during early and late acute rejection episodes in human cardiac allografts. Transplantation 2003; 75: 2044.
29. Carrington M, Dean M, Martin MP, O'Brien SJ. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999; 8: 1939.
30. Gonzalez E, Bamshad M, Sato N, et al. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci USA 1999; 96: 12004.
31. Mangano A, Gonzalez E, Dhanda R, et al. Concordance between that CC chemokine receptor 5 genetic determinants that alter the risk of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001; 183: 1574.
32. Tang J, Shelton B, Makhatadze NJ, et al. Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression. J Virol 2002; 76: 662.
33. Nomiyama H, Fukuda S, Iio M, et al. Organization of the chemokine gene cluster on human chromosome 17q11.2 containing the genes for CC chemokine MPIF-1, HCC-2, HCC-1, LEC, and RANTES. J Interferon Cytokine Res 1999; 19: 227.
34. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci USA 2001; 98: 5199.
35. Hancock WW. Chemokines receptor-dependent alloresponses. Immunol Res 2003; 196: 37.
36. Schroppel B, Fischereder M, Ashkar R, et al. The impact of polymorphisms in chemokine and chemokine receptors on outcomes in liver transplantation. Am J Transplant 2002; 2: 640.
37. Schroppel B, Fischereder M, Lin M, et al. Analysis of gene polymorphisms in the regulatory region of MCP-1, RANTES, and CCR5 in liver transplant recipients. J Clin Immunol 2002; 22: 381.
38. Kruger B, Schroppel B, Ashkan R, et al. A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. J Am Soc Nephrol 2002; 13: 2585.
39. Shieh B, Liau YE, Hsieh PS, et al. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol 2000; 12: 1311.
40. Salkowitz JR, Bruse SE, Meyerson H, et al. CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HLV-1 propagation in vitro. Clin Immunol 2003; 108: 234.
41. Nickel RG, Casolaro V, Wahn U, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol 2000; 164: 1612.
42. Belperio JA, Burdick MD, Keane MP, et al. The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol 2000; 165: 461.
43. Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001; 37: 518.
44. Fahmy NM, Yamani MH, Starling RC, et al. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003; 75: 72.